Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 21, 2014; 20(31): 11000-11011
Published online Aug 21, 2014. doi: 10.3748/wjg.v20.i31.11000
Published online Aug 21, 2014. doi: 10.3748/wjg.v20.i31.11000
Table 1 Acupoints selected for the treatment and control groups
Treatment group | Control group | |
Acupuncture points | Zusanli (ST36) | 20 mm away from the posterior of ST36 |
Shangjuxu (ST37) | 20 mm away from the posterior of ST37 | |
Gongsun (SP4) | On the medial aspect of the 1st cuneiform bone, between LR4 and SP4 | |
Sanyinjiao (SP6) | 15 mm away from the anterior of SP6, on the medial aspect of the tibia | |
Taixi (KI3) | 15 mm away from the anterior of KI3, on the medial aspect of the tibia | |
Taichong (LR3) | On the dorsal aspect of the 1st metatarsal bone between LR3 and SP3 | |
Moxibustion points | Tianshu (ST25), Qihai (CV6), Zhongwan (CV12) |
Table 2 Patient characteristics at baseline
Characteristics | Treatment group | Control group | P value1 |
Age (yr); mean ± SD | 36.98 ± 14.46 | 32.38 ± 11.83 | 0.113 |
Gender (male/female) | 27/16 | 25/17 | 0.757 |
Height (cm) | 167.47 ± 9.20 | 166.71 ± 6.79 | 0.670 |
Weight (kg) | 53.69 ± 11.73 | 53.44 ± 11.73 | 0.924 |
Duration of disease (yr) | 4.64 ± 3.75 | 4.67 ± 4.51 | 0.978 |
Prior resection (yes/no) | 8/35 | 4/38 | 0.229 |
Severity (mild/moderate) | 24/19 | 30/12 | 0.135 |
CDAI | 210.84 ± 48.03 | 201.04 ± 57.13 | 0.394 |
IBDQ | 157.67 ± 30.43 | 157.36 ± 33.19 | 0.963 |
HGB | 118.05 ± 17.79 | 124.79 ± 20.70 | 0.111 |
ESR | 21.80 ± 16.86 | 24.64 ± 22.28 | 0.625 |
CRP | 18.52 ± 24.35 | 12.32 ± 13.43 | 0.164 |
Concomitant medication | 27 | 24 | 0.398 |
Aminosalicylates | 16 | 11 | |
Corticosteroids | 2 | 3 | |
Aminosalicylates and corticosteroids | 9 | 10 | |
Montreal classification | |||
Age at diagnosis | |||
A1 | 2 | 3 | 0.373 |
A2 | 32 | 33 | |
A3 | 9 | 6 | |
Location | |||
L1 | 6 | 8 | 0.251 |
L2 | 8 | 11 | |
L3 | 29 | 23 | |
L4 | 0 | 0 | |
Behavior | |||
B1 | 12 | 9 | 0.853 |
B2 | 2 | 2 | |
B3 | 10 | 12 | |
B1P | 7 | 10 | |
B2P | 3 | 1 | |
B3P | 9 | 8 |
Table 3 Results of the main outcome measurement: Crohn’s disease activity index score (per-protocol and intention-to-treat analysis) (mean ± SD)
Analysis set | Group | n | Baseline | Changes from baseline to post-treatment | P value1 | n | Changes from baseline to follow up | P value1 |
PP analysis | Treatment | 43 | 210.84 ± 48.03 | -115.35 ± 55.05b | 0.000 | 40 | -128.93 ± 64.46b | 0.000 |
Control | 42 | 201.04 ± 57.13 | -35.68 ± 46.91b | 37 | -14.32 ± 52.09 | |||
ITT analysis | Treatment | 46 | 211.81 ± 50.97 | -107.83 ± 60.47b | 0.000 | 46 | -117.85 ± 70.10b | 0.000 |
Control | 46 | 200.20 ± 54.91 | -32.58 ± 45.91b | 46 | -22.19 ± 55.31b |
Table 4 Results of the total efficacy evaluation (per-protocol and intention-to-treat analysis analysis)
Analysis set | Group | n | Clinical remission | Improved | Ineffective | P value |
PP analysis | Treatment | 43 | 32 | 4 | 7 | 0.000 |
Control | 42 | 15 | 2 | 25 | ||
ITT analysis | Treatment | 46 | 32 | 4 | 10 | 0.000 |
Control | 46 | 15 | 2 | 29 |
Table 5 Results of the secondary outcome measures (n = 85) (mean ± SD)
Outcome measures | Group | Baseline | Post-treatment | Changes from baseline to post-treatment | P value |
IBDQ | Treatment | 157.67 ± 30.43 | 182.23 ± 33.07b | 24.56 ± 34.15 | 0.017 |
Control | 157.36 ± 33.19 | 167.29 ± 29.85b | 9.93 ± 19.13 | ||
HGB | Treatment | 118.05 ± 17.79 | 123.14 ± 20.87a | 5.09 ± 14.45 | 0.029 |
(g/L) | Control | 124.79 ± 20.70 | 123.86 ± 21.23 | -0.93 ± 10.07 | |
ESR | Treatment | 21.80 ± 16.86 | 17.85 ± 14.14 | -3.77 ± 13.00 | 0.163 |
(mm/h) | Control | 24.64 ± 22.28 | 24.41 ± 22.10 | -0.21 ± 10.12 | |
CRP | Treatment | 18.52 ± 24.35 | 8.71 ± 8.94b | -8.67 ± 20.04 | 0.008 |
(mg/L) | Control | 12.32 ± 13.43 | 13.60 ± 14.81 | 1.16 ± 12.11 | |
CDEIS | Treatment | 9.92 ± 8.94 | 7.64 ± 6.84 | -2.28 ± 5.52 | 0.380 |
Control | 6.15 ± 3.90 | 5.54 ± 4.79 | -0.60 ± 4.75 | ||
HS | Treatment | 11.2 ± 1.47 | 9.00 ± 2.11b | -2.2 ± 2.21 | 0.029 |
Control | 11.07 ± 1.44 | 10.53 ± 2.13 | -0.53 ± 1.73 |
Table 6 Changes in Crohn’s disease activity index scores according to subgroup (baseline to post treatment) (n = 85) (mean ± SD)
Subgroup (treatment group/control group) | Treatment group | Control group | P value1 |
Sex | |||
Male (27/25) | -118.84 ± 47.29 | -48.97 ± 51.95 | 0.001 |
Female (16/17) | -109.48 ± 67.45 | -16.14 ± 30.12 | 0.001 |
CDAI at baseline | |||
CDAI ≤ 220 (24/30) | -110.18 ± 49.51 | -26.87 ± 43.11 | 0.001 |
CDAI > 220 (19/12) | -121.89 ± 62.10 | -57.70 ± 50.59 | 0.005 |
Treatment with corticosteroids | |||
Yes (11/13) | -131.30 ± 34.25 | -28.86 ± 32.35 | 0.001 |
No (32/29) | -109.87 ± 60.05 | -38.73 ± 52.36 | 0.001 |
Location | |||
L1-Ileal (6/8) | -96.77 ± 55.42 | -19.70 ± 51.42 | 0.020 |
L2-Colonic (8/11) | -114.31 ± 34.93 | -50.29 ± 46.47 | 0.005 |
L3-Ileocolonic (29/23) | -119.49 ± 60.00 | -34.25 ± 45.56 | 0.001 |
- Citation: Bao CH, Zhao JM, Liu HR, Lu Y, Zhu YF, Shi Y, Weng ZJ, Feng H, Guan X, Li J, Chen WF, Wu LY, Jin XM, Dou CZ, Wu HG. Randomized controlled trial: Moxibustion and acupuncture for the treatment of Crohn’s disease. World J Gastroenterol 2014; 20(31): 11000-11011
- URL: https://www.wjgnet.com/1007-9327/full/v20/i31/11000.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i31.11000